CD274 and neoplasm: In previous trials with nivolumab, the association between PD-L1 IHC and outcome parameters in terms of the overall response rate (ORR), OS and PFS has been conflicting.4,5,34 In our study, we found that tumour PD-L1 expression was associated with DCB, and with OS in only the derivation cohort.